Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction Approximately 10% of all breast cancer cases occur in individuals who have germline pathogenic variants of the BRCA 1, BRCA 2, and other genes associated with impaired DNA damage repair that is associated with an increased risk of breast, ovarian, and other cancers. Inhibitors of poly-ADP ribose polymerase (PARP) induce synthetic lethality in cancer cells harboring such pathogenic variants. Area covered In this review, the authors review the mechanisms of action, antitumor activity, and adverse events associated with PARP inhibitors for the treatment of advanced breast cancer. The authors then summarize the area and provide their expert perspectives on the area. Expert opinion Two PARP inhibitors are approved in metastatic breast cancer, including olaparib and talozaparib. Both agents were approved based on phase III trials demonstrating that they were associated with improved progression-free survival compared with treatment of physician’s choice in patients receiving second-third line therapy for locally advanced, inoperable, or metastatic breast cancer in patients with germline pathogenic BRCA 1 or BRCA2 variants.

Original languageEnglish (US)
Pages (from-to)981-1003
Number of pages23
JournalExpert Opinion on Pharmacotherapy
Volume22
Issue number8
DOIs
StatePublished - 2021

Keywords

  • BRCA 1 or 2 mutation
  • breast cancer
  • DNA repair defect
  • PARP inhibitor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer'. Together they form a unique fingerprint.

Cite this